2024-11-04 15:11 | UU:JNJ | | News Release200 | Empower 2024 Delivers Groundbreaking Insights and Innovation to Achieve Data-Driven Healthcare |
2024-10-28 15:40 | UU:JNJ | | SEDAR Interim Financial Statements812 | SEDAR Interim MD & A |
2024-10-28 07:30 | UU:JNJ | | News Release200 | TREMFYA(TM) (guselkumab) is the first and only IL-23 inhibitor to demonstrate robust results with a fully subcutaneous regimen in both induction and maintenance in Crohn's disease |
2024-10-25 08:05 | UU:JNJ | | News Release200 | New SPECTREM study findings reveal TREMFYA(TM) (guselkumab) effectively clears overlooked and undertreated plaque psoriasis |
2024-10-24 08:00 | UU:JNJ | | News Release200 | Johnson & Johnson highlights innovative neuropsychiatry portfolio and pipeline at Psych Congress |
2024-10-15 08:00 | UU:JNJ | | News Release200 | Nipocalimab demonstrates sustained disease control in adolescents living with generalized myasthenia gravis in Phase 2/3 study |
2024-10-15 06:25 | UU:JNJ | | News Release200 | Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2024 |
2024-10-15 06:20 | UU:JNJ | | News Release200 | Johnson & Johnson Reports Q3 2024 Results |
2024-10-10 16:30 | UU:JNJ | | News Release200 | Johnson & Johnson to Participate in the Stifel 2024 Healthcare Conference |
2024-10-10 08:00 | UU:JNJ | | News Release200 | TREMFYA(TM) (guselkumab) demonstrates impressive results across biologic-naive and biologic-refractory patients in Crohn's disease and ulcerative colitis |
2024-10-09 08:00 | UU:JNJ | | News Release200 | Johnson & Johnson Completes Acquisition of V-Wave |
2024-10-04 16:30 | UU:JNJ | | News Release200 | Johnson & Johnson to Participate in the Guggenheim Global Healthcare Conference |
2024-10-02 09:00 | UU:JNJ | | News Release200 | ERLEADA(TM) (apalutamide) demonstrates statistically significant and clinically meaningful improvement in overall survival compared to enzalutamide in patients with metastatic castration-sensitive prostate cancer |
2024-09-30 16:05 | UU:JNJ | | News Release200 | Johnson & Johnson files for U.S. FDA approval of DARZALEX FASPRO(TM)-based quadruplet regimen for newly diagnosed multiple myeloma patients for whom transplant is not planned |
2024-09-30 08:05 | UU:JNJ | | News Release200 | Johnson & Johnson Rolls Out New TECNIS Odyssey Next-Generation Intraocular Lens Offering Cataract Patients Precise Vision at Every Distance in Any Lighting |
2024-09-27 16:30 | UU:JNJ | | News Release200 | CARVYKTI(TM) is the first and only cell therapy to significantly extend overall survival versus standard therapies for patients with multiple myeloma as early as second line |
2024-09-27 13:05 | UU:JNJ | | News Release200 | DARZALEX(TM) (daratumumab)-based maintenance regimens show clinically meaningful deep and durable responses in transplant-eligible patients with newly diagnosed multiple myeloma |
2024-09-27 13:00 | UU:JNJ | | News Release200 | DARZALEX FASPRO(TM)-based quadruplet regimen significantly improves minimal residual disease negativity for newly diagnosed multiple myeloma patients for whom transplant is not planned |
2024-09-27 08:05 | UU:JNJ | | News Release200 | Novel combination of TALVEY(TM) (talquetamab-tgvs) and TECVAYLI(TM) (teclistamab-cqyv) suggests high response rates and durable responses in triple-class refractory patients with relapsed or refractory multiple myeloma, including those with extramedullary |
2024-09-27 08:00 | UU:JNJ | | News Release200 | TALVEY(TM) (talquetamab-tgvs) and DARZALEX FASPRO(TM) (daratumumab and hyaluronidase-fihj) based combination shows deep and durable responses in patients with relapsed or refractory multiple myeloma |
2024-09-20 15:43 | UU:JNJ | | News Release200 | Johnson & Johnson Announces that its Subsidiary, Red River Talc LLC, has Filed a Voluntary Prepackaged Chapter 11 Case to Resolve All Current and Future Ovarian Cancer Talc Claims |
2024-09-19 18:54 | UU:JNJ | | News Release200 | RYBREVANT(TM) (amivantamab-vmjw) plus standard of care approved in the U.S. as first and only targeted regimen to cut risk of disease progression by more than half in second-line EGFR-mutated advanced lung cancer |
2024-09-16 02:50 | UU:JNJ | | News Release200 | Neoadjuvant TAR-200 plus cetrelimab nearly doubles the pathological complete response rate compared to cetrelimab alone in patients with muscle-invasive bladder cancer |
2024-09-15 02:30 | UU:JNJ | | News Release200 | New data from TAR-200 Phase 2b SunRISe-1 study show 84 percent complete response rate in patients with high-risk non-muscle-invasive bladder cancer |
2024-09-14 09:45 | UU:JNJ | | News Release200 | RYBREVANT(TM) (amivantamab-vmjw) plus chemotherapy show 49 percent overall response rate in metastatic colorectal cancer |
2024-09-14 03:10 | UU:JNJ | | News Release200 | RYBREVANT(TM) (amivantamab-vmjw) plus chemotherapy shows positive overall survival trend versus chemotherapy in patients with previously treated EGFR-mutated lung cancer |
2024-09-11 18:22 | UU:JNJ | | News Release200 | TREMFYA(TM) (guselkumab) receives U.S. FDA approval for adults with moderately to severely active ulcerative colitis, strengthening Johnson & Johnson's leadership in inflammatory bowel disease |
2024-09-10 17:15 | UU:JNJ | | News Release200 | Dexamethasone reduces infusion-related reactions in patients with EGFR-mutated non-small cell lung cancer treated with intravenous RYBREVANT(TM) (amivantamab-vmjw) |
2024-09-08 13:47 | UU:JNJ | | News Release200 | RYBREVANT(TM) (amivantamab-vmjw) plus LAZCLUZE(TM) (lazertinib) show strong favorable overall survival trend versus osimertinib in EGFR-mutated advanced lung cancer |
2024-09-05 16:30 | UU:JNJ | | News Release200 | Johnson & Johnson to Host Investor Conference Call on Third-Quarter Results |
2024-08-29 08:00 | UU:JNJ | | News Release200 | Johnson & Johnson seeks first approval of nipocalimab to treat broadest population living with antibody positive generalized myasthenia gravis |
2024-08-27 08:00 | UU:JNJ | | News Release200 | Johnson & Johnson is transforming solid tumor cancer outcomes with new data at the 2024 World Conference on Lung Cancer and European Society for Medical Oncology Congress |
2024-08-26 08:00 | UU:JNJ | | News Release200 | Johnson & Johnson's Executive Vice President, Chief Human Resources Officer Peter Fasolo to Retire; Kristen Mulholland Named Chief Human Resources Officer, Effective October 1, 2024 |
2024-08-20 07:30 | UU:JNJ | | News Release200 | Johnson & Johnson to Acquire V-Wave |
2024-08-20 07:00 | UU:JNJ | | News Release200 | RYBREVANT(TM) (amivantamab-vmjw) plus LAZCLUZE(TM) (lazertinib) approved in the U.S. as a first-line chemotherapy-free treatment for patients with EGFR-mutated advanced lung cancer |
2024-08-07 17:00 | UU:JNJ | | News Release200 | Groundbreaking nipocalimab study of pregnant individuals at high risk for early onset severe hemolytic disease of the fetus and newborn published in The New England Journal of Medicine |
2024-08-06 09:00 | UU:JNJ | | News Release200 | Alzheimer's Disease Diagnostics & Therapeutics Market Driven by Use of Biomarkers and Advancing R&D Activities |
2024-07-30 18:45 | UU:JNJ | | SEDAR Interim Financial Statements812 | SEDAR Interim MD & A |
2024-07-30 18:42 | UU:JNJ | | News Release200 | DARZALEX FASPRO(TM) (daratumumab and hyaluronidase-fihj)-based quadruplet regimen approved in the U.S. for patients with newly diagnosed multiple myeloma who are transplant-eligible |
2024-07-29 16:00 | UU:JNJ | | News Release200 | Johnson & Johnson to Participate in the 2024 Wells Fargo Healthcare Conference |
2024-07-23 16:00 | UU:JNJ | | News Release200 | Johnson & Johnson to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference |
2024-07-22 08:00 | UU:JNJ | | News Release200 | Johnson & Johnson seeks U.S. FDA approval of SPRAVATO(TM) (esketamine) as the first and only monotherapy for adults with treatment-resistant depression |
2024-07-17 06:25 | UU:JNJ | | News Release200 | Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2024 |
2024-07-17 06:20 | UU:JNJ | | News Release200 | Johnson & Johnson reports Q2 2024 results |
2024-07-15 08:05 | UU:JNJ | | News Release200 | NKGen Biotech Appoints Dr. Marco Gottardis to its Board of Directors |
2024-07-11 07:30 | UU:JNJ | | News Release200 | Johnson & Johnson Strengthens Pipeline to Lead in Atopic Dermatitis With the Completion of the Acquisition of Yellow Jersey Therapeutics, Gaining Ownership of NM26 |
2024-07-02 07:30 | UU:JNJ | | News Release200 | CARVYKTI(TM) (ciltacabtagene autoleucel) achieved statistically significant and clinically meaningful improvement in overall survival in landmark CARTITUDE-4 study |
2024-06-28 11:30 | UU:JNJ | | News Release200 | Nipocalimab pivotal Phase 3 trial demonstrates longest sustained disease control in FcRn class for broadest population of myasthenia gravis patients |
2024-06-21 07:30 | UU:JNJ | | News Release200 | Johnson & Johnson Completes Acquisition of Proteologix, Inc. |
2024-06-20 16:30 | UU:JNJ | | News Release200 | Johnson & Johnson submits application to U.S. FDA seeking approval of TREMFYA(TM) (guselkumab) for the treatment of moderately to severely active Crohn's disease |
2024-06-20 08:00 | UU:JNJ | | News Release200 | TREMFYA(TM) (guselkumab) studies underscore its potential to be the only IL-23 inhibitor to offer both subcutaneous and intravenous induction |
2024-06-17 09:00 | UU:JNJ | | News Release200 | Acute Myeloid Leukemia is on the Rise as Biotechs Race to Develop Groundbreaking Therapies |
2024-06-17 08:00 | UU:JNJ | | News Release200 | Subcutaneous amivantamab Biologics License Application submitted to U.S. FDA for patients with EGFR-mutated non-small cell lung cancer |
2024-06-15 03:30 | UU:JNJ | | News Release200 | Late-breaking results show nipocalimab significantly improves Sjogren's disease activity in a Phase 2 study |
2024-06-14 08:00 | UU:JNJ | | News Release200 | TALVEY(TM) (talquetamab-tgvs) demonstrates highly durable, longer-term responses in patients with relapsed or refractory multiple myeloma |
2024-06-04 16:30 | UU:JNJ | | News Release200 | Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results |
2024-05-31 08:45 | UU:JNJ | | News Release200 | Johnson & Johnson Completes Acquisition of Shockwave Medical |
2024-05-30 14:35 | UU:JNJ | | SEDAR Interim Financial Statements812 | SEDAR Interim Financial Statements |
2024-05-29 17:48 | UU:JNJ | | News Release200 | Sarepta Therapeutics Set to Join S&P MidCap 400 |
2024-05-28 07:35 | UU:JNJ | | News Release200 | Numab Therapeutics Announces Johnson & Johnson to Acquire its Wholly-Owned Subsidiary Yellow Jersey Therapeutics Including Rights to NM26, a Bi-Specific Antibody for the Treatment of Atopic Dermatitis |
2024-05-28 07:30 | UU:JNJ | | News Release200 | Johnson & Johnson to Obtain Rights to a Clinical-Stage Bispecific Antibody to Address Distinct Patient Needs in Atopic Dermatitis |
2024-05-16 07:30 | UU:JNJ | | News Release200 | Johnson & Johnson to Acquire Proteologix, Inc. to Lead in Atopic Dermatitis Treatment |
2024-05-08 16:30 | UU:JNJ | | News Release200 | Johnson & Johnson to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference |
2024-05-08 15:11 | UU:JNJ | | SEDAR Interim MD & A813 | SEDAR Interim MD & A |
2024-05-06 16:05 | UU:JNJ | | News Release200 | Shockwave Medical Reports First Quarter 2024 Financial Results |
2024-05-01 06:30 | UU:JNJ | | News Release200 | Johnson & Johnson Announces Plan by its Subsidiary, LLT Management LLC, to Resolve All Current and Future Ovarian Cancer Talc Claims Through a Consensual "Prepackaged" Reorganization |
2024-04-22 16:30 | UU:JNJ | | News Release200 | Johnson & Johnson to Participate in the Bernstein's 40th Annual Strategic Decisions Conference (SDC) |
2024-04-20 01:28 | UU:JNJ | | SEDAR Annual Report803 | SEDAR MD & A |
2024-04-16 06:25 | UU:JNJ | | News Release200 | Johnson & Johnson Announces 62nd Consecutive Year of Dividend Increase; Raises Quarterly Dividend by 4.2% |
2024-04-16 03:20 | UU:JNJ | | News Release200 | CORRECTING and REPLACING Johnson & Johnson Reports Q1 2024 Results |
2024-04-08 18:06 | UU:JNJ | | News Release200 | Johnson & Johnson to Participate in the 2024 RBC Capital Markets Global Healthcare Conference |
2024-04-05 23:21 | UU:JNJ | | News Release200 | CARVYKTI(TM) is the First and Only BCMA-Targeted Treatment Approved by the U.S. FDA for Patients with Relapsed or Refractory Multiple Myeloma Who Have Received at Least One Prior Line of Therapy |
2024-04-05 06:31 | UU:JNJ | | News Release200 | Johnson & Johnson to Acquire Shockwave Medical |
2024-04-04 18:01 | UU:JNJ | | News Release200 | Johnson & Johnson Recommends Shareholders Reject "Mini-Tender" Offer by TRC Capital Investment Corporation |
2024-04-02 16:30 | UU:JNJ | | News Release200 | Johnson & Johnson to Participate in the BofA Securities Health Care Conference |
2024-03-12 09:15 | UU:JNJ | | News Release200 | Artelo Biosciences Selected as a Finalist in Johnson & Johnson's Innovation Challenge |
2024-03-11 16:30 | UU:JNJ | | News Release200 | Johnson & Johnson to Host Investor Conference Call on First-Quarter Results |
2024-03-07 08:33 | UU:JNJ | | News Release200 | Johnson & Johnson Completes Acquisition of Ambrx |
2024-03-01 15:59 | UU:JNJ | | News Release200 | RYBREVANT(TM) (amivantamab-vmjw) in Combination With Chemotherapy Is the First FDA Approved Therapy for First-line Treatment of Patients With Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations |
2024-02-20 16:26 | UU:JNJ | | News Release200 | TECVAYLI ‚ ® (teclistamab-cqyv) biweekly dosing approved by the U.S. FDA for the treatment of patients with relapsed or refractory multiple myeloma |
2024-02-14 16:30 | UU:JNJ | | News Release200 | Johnson & Johnson to Participate in the Barclays 26th Annual Global Healthcare Conference |
2024-02-12 16:10 | UU:JNJ | | News Release200 | Johnson & Johnson to Participate in the Leerink Global Biopharma Conference |
2024-02-02 16:10 | UU:JNJ | | News Release200 | Johnson & Johnson to Participate in the Raymond James 45th Annual Institutional Investors Conference |
2024-01-24 15:42 | UU:JNJ | | SEDAR Interim Financial Statements812 | SEDAR Interim Financial Statements |
2024-01-23 06:20 | UU:JNJ | | News Release200 | Johnson & Johnson Reports Q4 and Full-Year 2023 Results |
2024-01-08 07:30 | UU:JNJ | | News Release200 | Johnson & Johnson to Acquire Ambrx, Advancing Next Generation Antibody Drug Conjugates to Transform the Treatment of Cancer |
2024-01-02 08:00 | UU:JNJ | | News Release200 | Johnson & Johnson Announces Quarterly Dividend for First Quarter 2024 |
2023-12-19 12:05 | UU:JNJ | | SEDAR Interim MD & A813 | SEDAR Interim MD & A |
2023-12-12 11:40 | UU:JNJ | | SEDAR Interim Financial Statements812 | SEDAR Interim Financial Statements |
2023-12-11 16:15 | UU:JNJ | | News Release200 | Johnson & Johnson to Host Investor Conference Call on Fourth-Quarter Results |
2023-12-07 16:15 | UU:JNJ | | News Release200 | Johnson & Johnson to Participate in the 42nd Annual J.P. Morgan Healthcare Conference |
2023-12-07 13:31 | UU:JNJ | | SEDAR Interim Financial Statements812 | SEDAR Interim Financial Statements |
2023-12-05 07:15 | UU:JNJ | | News Release200 | Johnson & Johnson Announces Key Drivers for Long-Term Competitive Growth at Enterprise Business Review |
2023-11-30 16:30 | UU:JNJ | | News Release200 | Johnson & Johnson Names Eugene A. Woods, Chief Executive Officer of Advocate Health, to its Board of Directors |
2023-11-30 08:40 | UU:JNJ | | News Release200 | Johnson & Johnson MedTech Acquires Laminar, Inc. |
2023-11-16 07:30 | UU:JNJ | | News Release200 | Johnson & Johnson to Host Enterprise Business Review |